RYTM - Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday February 22 2024 | Benzinga
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.
Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming conferences:
- Guggenheim's 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 1:30 p.m. ET in New York, NY.
- and TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:50 p.m. ET in Boston, MA.
Live webcasts of both the earnings conference call and the fireside chats will be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at http://ir.rhythmtx.com/. The archived webcast of the conference call will be available on Rhythm's website approximately two hours after it concludes and will be available for 30 days following the call. A replay of the Guggenheim and Cowen webcasts will also be available on the Rhythm website for 30 days following the presentations.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm's lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program that includes investigational MC4R agonists LB54640 and RM-718, as well as a suite of preclinical candidates for the treatment of congenital hyperinsulinism. Rhythm's headquarters is in Boston, MA.
Setmelanotide Indication
In the United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1 or LEPR deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance ...